Drug Profile
Bimatoprost/timolol
Alternative Names: Ganfort; Lumigan/timolol; Timolol/bimatoprost; Unit Dose GanfortLatest Information Update: 21 Jan 2022
Price :
$50
*
At a glance
- Originator AbbVie; Allergan
- Class Amides; Antiglaucomas; Antihypertensives; Lipids; Morpholines; Propanolamines; Synthetic prostaglandins; Thiadiazoles
- Mechanism of Action Beta-adrenergic receptor antagonists; Prostaglandin F2alpha receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Glaucoma; Ocular hypertension
Most Recent Events
- 08 May 2020 Allergan has been acquired and merged into AbbVie
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Glaucoma in China (Ophthalmic, Drops)
- 01 Jan 2013 Allergan files for approval of a preservative-free bimatoprost/timolol formulation in the EU